In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships

Executive Summary

While pharma needs to access biotech's innovation, biotechs and their investors are unwilling to cede late-stage control. This is a recipe for stalemate: the industry needs different partnership structures which fully pay biotech for innovation (with royalties of 20% or more) and leave early-stage development in their hands, while allowing Big Pharma to do the later-stage development and commercialization. To afford these deals, however, Pharma needs to cut their own spending on innovation.
Advertisement

Related Content

After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation
Isis: Pondering Platform Power
Isis: Pondering Platform Power
Third Rock Rolls
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
Theravance: Having Cake and Eating It
Enzon: The Perils of Profitability

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel